Alnylam Pharmaceuticals, Inc.
ALNYNASDAQHealthcare● Active
$288.89
$-14.16(-4.67%)
Market Cap$38.6B
P/E Ratio—
52W High$495.55
52W Low$283.1
Alnylam Pharmaceuticals, Inc. (ALNY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALNY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $0.84B |
| Cost of Revenue | $0.68B | $0.32B | $0.31B | $0.17B | $0.14B |
| Gross Profit | $3.04B | $1.92B | $1.52B | $0.87B | $0.70B |
| Gross Margin %(computed) | 81.77% | 85.62% | 83.02% | 83.73% | 83.40% |
| Operating Expenses | |||||
| R&D Expenses | $1.32B | $1.13B | $1.00B | $0.88B | $0.79B |
| G&A Expenses | $0.00B | $0.98B | $0.80B | $0.77B | $0.62B |
| Total Operating Expenses | $2.54B | $2.10B | $1.80B | $1.65B | $1.41B |
| Operating Income | $0.50B | ($0.18B) | ($0.28B) | ($0.79B) | ($0.71B) |
| Operating Margin %(computed) | 13.51% | -7.87% | -15.43% | -75.68% | -83.93% |
| Interest Income | $0.11B | $0.12B | $0.10B | $0.02B | $0.00B |
| Interest Expense | $0.25B | $0.14B | $0.12B | $0.16B | $0.14B |
| Income Before Tax | $0.32B | ($0.38B) | ($0.43B) | ($1.13B) | ($0.85B) |
| Income Tax Expense | $0.01B | ($0.10B) | $0.01B | $0.00B | $0.00B |
| Net Income | $0.31B | ($0.28B) | ($0.44B) | ($1.13B) | ($0.85B) |
| Net Margin %(computed) | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| Wtd Avg Shares | 0.13B | 0.13B | 0.12B | 0.12B | 0.12B |
| EBITDA | $0.56B | ($0.18B) | ($0.26B) | ($0.93B) | ($0.66B) |
| EBITDA Margin %(computed) | 15.00% | -7.95% | -14.12% | -89.31% | -78.36% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Alnylam Pharmaceuticals, Inc. data
About Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement
Alnylam Pharmaceuticals, Inc. (ALNY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ALNY reported revenue of $3.71B, gross profit of $3.04B (gross margin 81.77%), and net income of $0.31B — a net profit margin of 8.45%.
Frequently asked questions
ALNY · 4 questionsAlnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $3.71B for 2025, up 65.2% year-over-year.
ALNY revenueALNY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08